Nouri Alaleh

CLO Nouri Alaleh sold 28.1K shares ($2.7M) at $97.13 avg; post-sale holds 52.5K shares at unprofitable PRCT.

Nouri Alaleh, PROCEPT's EVP, CLO, and Corporate Secretary, executed 3 separate sales totaling 28,092 shares for $2,728,573.90 on 2024-12-04, reducing his holdings by 34.9% to 52.5K shares. The sales occurred at prices ($96.12, $96.98, $97.90) near the stock's 52-week high of $99.45, while the company remains unprofitable with a $-21.0M net loss in its latest full fiscal year despite strong 81.6% annual revenue growth. Across his prior 5 open-market sales at PRCT, only 1 of 5 proved well-timed at the 90-day mark, suggesting inconsistent predictive signal; his cross-ticker track record shows 25.00% well-timed rate and average 90d return of +12.1% after sells, indicating sells tend to precede further gains rather than declines. The stock has fallen 4.6% from its 52-week high and is down 3.4% over 30 days, but the transaction's significance is moderate given the mixed historical timing pattern and the company's ongoing profitability challenge.

EVP, CLO sells 10,000 PRCT shares for $621,763.92; holds 52,472 post-sale; stock down -10.4% from 52-week high.

Nouri Alaleh, EVP and Chief Legal Officer, executed 2 separate sales totaling 10,000 shares for $621,763.92 at a blended average price of $62.18, reducing holdings by 16.0% to 52,472 shares. The sale occurred as PRCT shares are -10.4% from the 52-week high of $69.19 and down -9.0% over the prior 30 days, suggesting the insider liquidated a meaningful portion at a point of relative weakness. The company remains unprofitable (net income of $-26.0M in the latest quarter) despite strong annual revenue growth of +81.6%, which underscores execution risk in a high-burn, high-growth profile. The insider's cross-ticker sell track record shows an average 90-day return of +17.9% after sales, indicating poor timing historically (stock rose after the insider sold); however, at this specific ticker (PRCT), all 5 prior measurable sales from 2024-05-03 showed positive 30-day returns (+3.7% to +9.1%), suggesting those earlier exits preceded or occurred during broader strength. This current June sale at lower prices—with the stock having already declined significantly from early-May levels—warrants monitoring against the unfolding fundamental and price trajectory.